Armatus Bio Inc.’s development of ARM-201, an AAV-delivered microRNA therapy for facioscapulohumeral muscular dystrophy (FSHD), has been boosted by a $3 million investment by Solve FSHD.
Solid Biosciences Inc. has announced a nonexclusive worldwide license and collaboration agreement with Armatus Bio Inc. for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat facioscapulohumeral muscular dystrophy (FSHD).
The Charcot-Marie-Tooth Association (CMTA) has participated in a seed extension round for Armatus Bio Inc., an emerging biotechnology company that is advancing a unique gene therapy clinical candidate to target Charcot-Marie-Tooth (CMT) type 1A.
